Vivimed Labs Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: VIVIMEDLAB BSE: 532660

₹5.44

Sept. 30, 2026 · NSE · nse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

Company	Market cap (₹ Cr)	PE (TTM)	ROE	1Y return	Div. yield	Quality	Valuation	Momentum
Sun Pharmaceutical Industries Limited	435,863	146.5	13.7%	11.0%	—	72	8	30
Divi's Laboratories Limited	246,660	83.9	15.3%	62.7%	0.32%	70	4	51
Torrent Pharmaceuticals Limited	162,454	78.2	12.2%	34.6%	0.79%	56	0	31
Zydus Lifesciences Limited	115,910	33.3	17.3%	17.2%	0.09%	74	24	84
Cipla Limited	108,736	35.4	11.2%	-11.0%	0.97%	73	29	62
Laurus Labs Limited	106,969	122.5	17.1%	127.1%	—	78	24	53
Mankind Pharma Limited	103,406	47.4	11.7%	2.6%	—	68	12	86
Dr. Reddy's Laboratories Limited	102,916	154.7	10.9%	-0.9%	—	62	33	71

Valuation multiples

Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet. EBITDA = PBT + interest + depreciation.

Enterprise value

Data unavailable.

EV / EBITDA

Data unavailable.

EV / Sales

Data unavailable.

Market cap / Sales

Data unavailable.

Earnings yield

Data unavailable.

Quarterly Financials

Download CSV

Standalone Consolidated

↓ Negative

Quarterly Revenue

Mar 2026 quarterly revenue is Rs 8 Cr, down 71.7% YoY.

↑ Positive

Quarterly Net Profit

Mar 2026 quarterly net profit is Rs -141 Cr, up 3579.4% YoY.

Period end	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)	Basic EPS
March 31, 2026	8	-141	-141	₹-17.1400
Dec. 31, 2025	12	-17	-17	₹-2.0000
Sept. 30, 2025	19	-7	-7	₹-0.9000
June 30, 2025	18	-5	-5	₹-0.6600
March 31, 2025	23	-4	-4	₹
Dec. 31, 2024	34	-7	-7	₹-0.8400
Sept. 30, 2024	22	-5	-5	₹-0.6000
June 30, 2024	25	-8	-8	₹-1.8200
March 31, 2024	36	7	6	₹0.6650
Dec. 31, 2023	37	-17	-16	₹-1.9500
Sept. 30, 2023	30	-20	-20	₹-2.3600
June 30, 2023	33	-15	-15	₹1.8600
March 31, 2023	40	-267	-265	₹-31.9400

Quarterly income statement (standalone, ₹ Cr)

Indicator	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23
Total income (before exceptional items)	8	—	19	18	27	34	22	25	44	37	32	33	—
Operating revenue	8	12	19	18	23	34	22	25	36	37	30	33	40
Other income	0	—	0	0	4	0	0	0	7	0	2	0	—
Operating expenses	144	23	20	18	24	34	23	36	-2	36	36	33	203
Operating profit	-136	-11	-1	-1	-2	-0	-1	-11	39	1	-5	-0	-164
Operating profit margin	-1802.7%	-96.5%	-7.1%	-3.0%	-8.4%	-0.5%	-3.5%	-45.0%	106.0%	2.4%	-17.9%	-0.9%	-412.3%
Depreciation	4	4	5	5	5	6	4	4	5	4	4	4	95
Interest	1	1	2	1	1	0	0	0	34	13	12	11	8
Exceptional items, gain / (loss)	—	—	—	—	—	—	—	—	—	—	—	—	—
Profit before tax	-141	-17	-7	-5	-4	-7	-5	-15	7	-17	-20	-15	-267
Tax	—	—	—	—	—	—	—	—	2	-1	—	—	-2
Net profit	-141	-17	-7	-5	-4	-7	-5	-15	6	-16	-20	-15	-265
EPS	-17.14	-2.00	-0.90	-0.66	—	-0.84	-0.60	-1.82	0.67	-1.95	-2.36	1.86	-31.94
Net profit (TTM)	-171	-33	-24	-21	-31	-22	-31	-45	-46	-316	-319	-322	-328
EPS (TTM)	-20.70	—	—	—	—	-2.60	-3.71	-5.47	-1.79	-34.39	-32.67	-32.98	-37.49

Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.

Annual Financials

Year ended	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)
March 31, 2026	56	-171	-171
March 31, 2025	104	-31	-31
March 31, 2024	137	-44	-44
March 31, 2023	177	-330	-328

Annual income statement (standalone, ₹ Cr; CAGR to the latest year)

Indicator	CAGR 3Y	CAGR 5Y	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17	Mar 16
Total income (before exceptional items)	—	—	—	108^†	146^†	—	220^†	216^†	283^†	260^†	263^†	—	—
Operating revenue	-31.9%	-23.3%	56	104	137	177	218^†	210^†	277^†	252^†	261^†	506^†	320^†
Other income	—	—	—	4^†	10^†	—	1^†	6^†	7^†	9^†	2^†	—	—
Operating expenses	—	—	205^†	118^†	103^†	365^†	228^†	188^†	244^†	185^†	185^†	211^†	178^†
Operating profit	—	—	-149^†	-14^†	34^†	-188^†	-9^†	22^†	32^†	67^†	77^†	295^†	142^†
Operating profit margin	—	—	-267.4%^†	-13.5%^†	24.7%^†	-106.4%^†	-4.2%^†	10.4%^†	11.7%^†	26.7%^†	29.3%^†	58.3%^†	44.4%^†
Depreciation	—	—	18^†	19^†	18^†	107^†	17^†	16^†	17^†	18^†	18^†	22^†	19^†
Interest	—	—	4^†	3^†	69^†	35^†	40^†	41^†	43^†	52^†	52^†	51^†	56^†
Exceptional items, gain / (loss)	—	—	0^†	0^†	0^†	0^†	0^†	0^†	0^†	0^†	0^†	0^†	0^†
Profit before tax	—	—	-171	-31	-44	-330	-65^†	-29^†	-21^†	5^†	9^†	187^†	11^†
Tax	—	—	—	—	—	—	—	—	—	-1^†	-1^†	49^†	—
Net profit	—	—	-171	-31	-44	-328	-68^†	-29^†	-19^†	6^†	10^†	138^†	8^†
EPS	—	—	-20.70^†	—	-1.79^†	-37.49^†	-8.41^†	-3.55^†	-2.32^†	—	—	—	—

^† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.

Annual ratios (standalone)

Ratio	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17	Mar 16
Operating margin	-267.4%^†	-13.5%^†	24.7%^†	-106.4%^†	-4.2%^†	10.4%^†	11.7%^†	26.7%^†	29.3%^†	58.3%^†	44.4%^†
EBIT margin	-299.1%^†	-27.4%^†	18.2%^†	-166.7%^†	-11.6%^†	5.7%^†	8.0%^†	22.8%^†	23.1%^†	47.0%^†	21.0%^†
PBT margin	-306.0%	-29.8%	-32.4%	-186.7%	-29.7%^†	-14.0%^†	-7.5%^†	2.0%^†	3.3%^†	36.9%^†	3.5%^†
Net margin	-306.0%	-29.8%	-32.4%	-185.5%	-31.0%^†	-14.0%^†	-6.9%^†	2.4%^†	3.7%^†	27.3%^†	2.5%^†
Interest coverage	-43.25x^†	-11.22x^†	0.36x^†	-8.36x^†	-0.64x^†	0.29x^†	0.52x^†	1.10x^†	1.17x^†	4.68x^†	1.20x^†
Dividend payout	—	—	—	—	—	—	—	—	—	—	—
Earnings retention	—	—	—	—	—	—	—	—	—	—	—
Current ratio	0.34x	0.63x	—	—	—	—	—	—	—	—	—
Quick ratio	0.31x	0.49x	—	—	—	—	—	—	—	—	—
Debt to equity	—	—	—	—	—	—	—	—	—	—	—
Return on equity	—	—	—	—	—	—	—	—	—	—	—
Return on assets	-34.0%	-4.8%	—	—	—	—	—	—	—	—	—
Return on capital employed	-207.6%^†	-11.6%^†	—	—	—	—	—	—	—	—	—
Asset turnover	0.11x	0.16x	—	—	—	—	—	—	—	—	—

Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.

Revenue Mix

Data unavailable.

Cash Flow

Year ended	Operating (₹ Cr)	Investing (₹ Cr)	Financing (₹ Cr)	Capex (₹ Cr)	Free Cash Flow (₹ Cr)
March 31, 2026	4	-0	-5	0	4
March 31, 2025	6	-4	-3	0	6
March 31, 2024	-97	100	-6	0	-97
March 31, 2023	14	-2	-16	0	14
March 31, 2022	25	-11	-13	11	14

Balance Sheet (standalone)

Year ended	Total Assets (₹ Cr)	Total Equity (₹ Cr)	Reserves (₹ Cr)	Borrowings, Current (₹ Cr)	Borrowings, Non-current (₹ Cr)	Current Assets (₹ Cr)	Current Liabilities (₹ Cr)	Cash & Equivalents (₹ Cr)	Net Block (₹ Cr)	Inventory (₹ Cr)
March 31, 2026	502	-112	-129	317	71	142	422	0	231	11
March 31, 2025	639	—	—	—	—	248	393	0	248	56
March 31, 2024	—	—	—	—	—	—	—	—	—	—
March 31, 2023	—	—	—	—	—	—	—	—	—	—
March 31, 2022	—	—	—	—	—	—	—	—	—	—

Financial charts

Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.